Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH1 Dendritic Cell Immunotherapy in Cutaneous Angiosarcoma
NCT05799612Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2024
- Primary completion
- Nov 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
01
Overview
Phase 1, open-label, single-arm trial in angiosarcoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Planned start Mar 2024; status: withdrawn.
02
Conditions
angiosarcoma
Beyond the preview
Go deeper on NCT05799612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05799612.